DE3889927D1 - Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen. - Google Patents

Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.

Info

Publication number
DE3889927D1
DE3889927D1 DE3889927T DE3889927T DE3889927D1 DE 3889927 D1 DE3889927 D1 DE 3889927D1 DE 3889927 T DE3889927 T DE 3889927T DE 3889927 T DE3889927 T DE 3889927T DE 3889927 D1 DE3889927 D1 DE 3889927D1
Authority
DE
Germany
Prior art keywords
sequences
autoimmune diseases
iddm
antibodies
dna sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3889927T
Other languages
English (en)
Other versions
DE3889927T2 (de
Inventor
Henry Erlich
Glenn Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22397216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3889927(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE3889927D1 publication Critical patent/DE3889927D1/de
Publication of DE3889927T2 publication Critical patent/DE3889927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE3889927T 1987-11-17 1988-11-14 Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen. Expired - Lifetime DE3889927T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/121,519 US6194561B1 (en) 1986-03-13 1987-11-17 Characterization and detection of sequences associated with autoimmune diseases
PCT/US1988/004067 WO1989004875A2 (en) 1987-11-17 1988-11-14 Characterization and detection of sequences associated with autoimmune diseases

Publications (2)

Publication Number Publication Date
DE3889927D1 true DE3889927D1 (de) 1994-07-07
DE3889927T2 DE3889927T2 (de) 1994-11-03

Family

ID=22397216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3889927T Expired - Lifetime DE3889927T2 (de) 1987-11-17 1988-11-14 Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.

Country Status (7)

Country Link
US (2) US6194561B1 (de)
EP (1) EP0439458B1 (de)
JP (1) JP2877165B2 (de)
AT (1) ATE106454T1 (de)
CA (1) CA1339098C (de)
DE (1) DE3889927T2 (de)
WO (1) WO1989004875A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010589A1 (en) * 1990-12-06 1992-06-25 F. Hoffmann-La Roche Ag Methods and reagents for hla drbeta dna typing
US5567809A (en) * 1986-03-13 1996-10-22 Hoffmann-La Roche Inc. Methods and reagents for HLA DRbeta DNA typing
US5310893A (en) * 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
US5714380A (en) * 1986-10-23 1998-02-03 Amoco Corporation Closed vessel for isolating target molecules and for performing amplification
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9002625D0 (en) * 1990-02-06 1990-04-04 Univ Singapore Human leukocyte antigen typing
ES2090335T3 (es) * 1990-05-01 1996-10-16 Univ Leland Stanford Junior Composiciones para uso en un metodo para tratar a un ser humano que padece esclerosis multiple.
US7294712B2 (en) * 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
CA2049449C (en) * 1990-08-20 1999-08-10 Fumiya Obata Hla-dr antigen gene and its nucleotide sequence and its use
DE69125368T2 (de) * 1990-12-21 1997-10-09 Hoffmann La Roche Karakterisierung von hla-dqbeta-dns
KR100227303B1 (ko) * 1991-02-12 1999-12-01 장-끌로드 비에이으포스 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도
US5976789A (en) * 1991-07-17 1999-11-02 Bio Merieux System of probes enabling HLA-DR typing to be performed, and typing method using said probes
FR2679252B1 (fr) * 1991-07-17 1993-12-10 Bio Merieux Systeme de sondes permettant d'effectuer le typage hla dr, et procede de typage utilisant lesdites sondes.
FR2684688B1 (fr) * 1991-12-04 1994-03-18 Bertin Et Cie Procede de selection d'au moins un crible de mutations, son application a un procede d'identification rapide d'alleles de systemes polymorphes et dispositif pour sa mise en óoeuvre.
US5763591A (en) * 1996-03-25 1998-06-09 Cedars-Sinai Medical Center Polynucleic acid sequences that are functionally associated with the development of autoimmune disease
FR2749308B1 (fr) * 1996-06-03 1998-07-24 Bio Merieux Sondes nucleotidiques et procede pour determiner le typage hla dqb1
AU6435898A (en) * 1997-02-21 1998-09-09 Saigene Corporation Compositions and methods for determining predisposition to insulin dependent diabetes mellitus
US5985567A (en) * 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
EP1176199B1 (de) * 1999-04-26 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Tumorsuppressorgen
AU785071B2 (en) * 1999-11-01 2006-09-14 Shunichi Shiozawa Method of diagnosing rheumatoid arthritis
WO2004094986A2 (en) * 2003-04-16 2004-11-04 Handylab, Inc. System and method for electrochemical detection of biological compounds
EP1536021A1 (de) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Methode zur Typisierung von HLA
US20100086914A1 (en) * 2008-10-03 2010-04-08 Roche Molecular Systems, Inc. High resolution, high throughput hla genotyping by clonal sequencing
WO2009126740A1 (en) * 2008-04-09 2009-10-15 Pacific Northwest Research Institute Methods for screening for genetic predisposition to type i diabetes
US20100261189A1 (en) * 2008-10-03 2010-10-14 Roche Molecular Systems, Inc. System and method for detection of HLA Variants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) * 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3687064T2 (de) 1985-06-14 1993-11-11 Bristol Myers Squibb Co Verfahren zur identifizierung von mit gesteigerter diabetesgefahr assoziierten allelen.
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4965189A (en) 1986-07-01 1990-10-23 University Of Massachusetts Medical School Probes for the determination of the proclivity for development of autoimmune diseases
US5059519A (en) 1986-07-01 1991-10-22 University Of Massachusetts Medical School Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
DK495186D0 (da) * 1986-10-16 1986-10-16 Nordisk Gentofte Fremgangsmaade og middel til paavisning af genstrukturer hos personer med stor tilbaejelighed til udvikling af iddm
US5039606A (en) 1987-10-29 1991-08-13 Virginia Mason Research Center Diagnostic probe for diabetes type I predisposition
US4971902A (en) 1987-10-30 1990-11-20 Virginia Mason Research Center Diagnostic probe for rheumatoid arthritis predisposition

Also Published As

Publication number Publication date
US6194561B1 (en) 2001-02-27
EP0439458A1 (de) 1991-08-07
DE3889927T2 (de) 1994-11-03
EP0439458B1 (de) 1994-06-01
JPH03501926A (ja) 1991-05-09
ATE106454T1 (de) 1994-06-15
JP2877165B2 (ja) 1999-03-31
US5665548A (en) 1997-09-09
WO1989004875A2 (en) 1989-06-01
CA1339098C (en) 1997-07-29
WO1989004875A3 (en) 1989-06-15

Similar Documents

Publication Publication Date Title
DE3889927T2 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
Fehlmann et al. Molecular association between major histocompatibility complex class I antigens and insulin receptors in mouse liver membranes.
DK203489A (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
ATE319091T1 (de) Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20001668D0 (no) Anvendelse av et DNA-fragment, samt komplementære kjeder, derivater og deler derav
DE69033453T2 (de) Rekombinante Polypeptide und Peptide, dafür kodierende Nukleinsäuren und ihre Verwendung in der Tuberkulose-Diagnose
HUP0002472A2 (hu) Izolált dendritikus sejtmembrán-fehérje gének
Nairn et al. Isolation, characterization and amino acid sequence studies of the cyanogen bromide fragments of the H‐2 Dd glycoprotein
NO930428L (no) Proteinstrukturen til plantetoksingelonin
Van Schravendijk et al. Comparative structural analysis of HLA-A3 antigens distinguishable by cytotoxic T lymphocytes: variant E1.
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
Martinko et al. Primary structure of murine major histocompatibility complex alloantigens: completion of the sequence of the amino-terminal 284 residues of H-2Kb
ZA902831B (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p.falciparum at the sporozoite stage and in the hepatocytes
CA2109961A1 (en) Peptides for use in induction of t cell activation against hiv-1
Uehara et al. Primary structure of murine major histocompatibility alloantigens: amino acid sequence of the cyanogen bromide fragment Ia (positions 139-228) from the H-2Kb molecule
KR890009972A (ko) 펩티드, 이의 제조방법, 항체를 수득하기 위한 이의 용도, 및 인간 혈액중의 pai 1 활성을 억제하기 위한 항체의 용도
Nathenson et al. Structure of H-2 major histocompatibility complex products: recent studies on the H-2K b glycoprotein and on the H-2K b MHC mutants
PT87239A (pt) Process for the preparation of peptides
CN101052412B (zh) 阿米巴病亚单位疫苗
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition